文献速递肝病消化道肿瘤与早癌消化内镜

通往大流行恢复之路:追踪COVID-19对111,558名退伍军人肝硬化诊疗及结局的影响

The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 Veterans.
PubMed 文献 · Hepatology · 2023-01-30

本研究基于美国退伍军人健康管理局企业数据仓库,评估2018年9月30日至2022年3月31日期间肝硬化退伍军人的季度诊疗过程和健康结局趋势,并分析COVID-19大流行前后与肝硬化结局相关的因素。研究发现肝细胞癌半年筛查率从大流行前峰值41%降至最低28%,后回升至36%;全因死亡率无显著变化,但新发肝细胞癌诊断、食管静脉曲张监测或治疗、静脉曲张出血和全因住院率均显著下降;农村居住在大流行期间新近与未筛查显著相关。

要点

  • 肝硬化退伍军人肝细胞癌半年筛查率从大流行前峰值41%降至最低28%,2022年3月回升至36%。
  • 大流行期间全因死亡率无显著变化,但新发肝细胞癌、食管静脉曲张监测或治疗、静脉曲张出血及全因住院率均显著下降。
  • 农村居住在大流行期间新近与未筛查显著相关(HCC-6的aOR=0.80,95%CI 0.74至0.86;EVST的aOR=0.95,95%CI 0.90至0.997)。

核心结论

  • 大流行持续影响肝硬化诊疗,识别诊疗中断风险最高的人群可能有助于解决持续存在的需求领域。

研究设计与样本

  • 研究利用美国退伍军人健康管理局企业数据仓库识别肝硬化退伍军人,纳入111,558名,平均终末期肝病模型-钠评分为11±5。
  • 评估2018年9月30日至2022年3月31日的季度指标,包括肝细胞癌半年筛查、新发肝细胞癌、食管静脉曲张监测或治疗、静脉曲张出血、全因住院和死亡率。
  • 采用连接点分析评估趋势随时间的变化,采用逻辑回归模型识别与各结局相关的人口学和医学因素。

主要发现

  • 肝细胞癌半年筛查率从大流行前峰值41%急剧下降至最低28%,至2022年3月回升至36%。
  • 全因死亡率在大流行期间无显著变化,但新发肝细胞癌诊断、食管静脉曲张监测或治疗、静脉曲张出血和全因住院在随访期间显著下降。
  • 季度肝细胞癌诊断从0.49%降至0.38%,食管静脉曲张监测或治疗从50%降至41%,静脉曲张出血从0.15%降至0.11%,住院从9%降至5%。
  • 农村居住在大流行期间新近与未筛查显著相关(HCC-6的aOR=0.80,95%CI 0.74至0.86;EVST的aOR=0.95,95%CI 0.90至0.997)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AIMS: This study aimed to evaluate quarterly trends in process and health outcomes among Veterans with cirrhosis and assess the factors associated with cirrhosis outcomes before and during the COVID-19 pandemic. APPROACH RESULTS: US Veterans with cirrhosis were identified using the Veterans Health Administration Corporate Data Warehouse. Quarterly measures were evaluated from September 30, 2018, through March 31, 2022, including twice yearly screening for hepatocellular carcinoma (HCC-6), new HCC, surveillance for or treatment of esophageal varices, variceal bleeding, all-cause hospitalization, and mortality. Joinpoint analyses were used to assess the changes in trends over time. Logistic regression models were used to identify the demographic and medical factors associated with each outcome over time. Among 111,558 Veterans with cirrhosis with a mean Model for End-stage Liver Disease-Sodium of 11±5, rates of HCC-6 sharply declined from a prepandemic peak of 41%, to a nadir of 28%, and rebounded to 36% by March 2022. All-cause mortality did not significantly change over the pandemic, but new HCC diagnosis, EVST, variceal bleeding, and all-cause hospitalization significantly declined over follow-up. Quarterly HCC diagnosis declined from 0.49% to 0.38%, EVST from 50% to 41%, variceal bleeding from 0.15% to 0.11%, and hospitalization from 9% to 5%. Rurality became newly, significantly associated with nonscreening over the pandemic (aOR for HCC-6=0.80, 95% CI 0.74 to 0.86; aOR for EVST=0.95, 95% CI 0.90 to 0.997). CONCLUSIONS: The pandemic continues to impact cirrhosis care. Identifying populations at the highest risk of care disruptions may help to address ongoing areas of need.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Adejumo AC, Yakovchenko V, Morgan TR, et al. The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 Veterans. Hepatology. 2023. PMID: 36705024. doi:10.1097/HEP.0000000000000306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。